News

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisResults from the HERCULES phase 3 ...
PharmiWeb2d
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing ...
Pharmabiz1d
Sanofi announces tolebrutinib phase 3 study data published in NEJM shows benefit on disability progression in multiple sclerosis
Sanofi announces tolebrutinib phase 3 study data published in NEJM shows benefit on disability progression in multiple sclerosis: Paris Thursday, April 10, 2025, 10:00 Hrs [IST] T ...
Frontiers4d
Irreversible electroporation promotes a pro-inflammatory tumor microenvironment and anti-tumor immunity in a mouse pancreatic cancer model
Irreversible electroporation (IRE ... Blood sera was isolated from whole blood and assessed via enzyme-linked immunosorbent assay (ELISA) for a range of inflammatory mediators, including IFN-γ. U251 ...
Novel compounds target dual enzymes to combat hormone-resistant breast cancer
Researchers have found new compounds that could be used to treat a common breast cancer that can be resistant to hormone ...
Blocking an enzyme may improve melanoma immunotherapy outcomes
About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven ...
News-Medical.Net on MSN3d
Blocking an enzyme to overcome immunotherapy resistance in melanoma patients
About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven ...
Medscape1d
Rasagiline: A Second-Generation Monoamine Oxidase Type-B Inhibitor for the Treatment of Parkinson's Disease
Conclusion: Rasagiline is an investigational selective and irreversible inhibitor of MAO-B that has demonstrated efficacy and safety for the treatment of PD. Whether rasagiline is associated with ...
Science Daily3d
Targeted new approach to treat pancreatic cancer
Researchers have identified a new molecular target for treating pancreatic cancer. Scientists focused on transcription-replication conflicts (TRCs), which occur when the mechanisms responsible for ...